Last $48.88 USD
Change Today +0.62 / 1.28%
Volume 905.4K
INCY On Other Exchanges
Symbol
Exchange
NASDAQ GS
Frankfurt
As of 8:10 PM 09/18/14 All times are local (Market data is delayed by at least 15 minutes).

incyte corp (INCY) Snapshot

Open
$48.45
Previous Close
$48.26
Day High
$49.41
Day Low
$47.85
52 Week High
02/26/14 - $70.86
52 Week Low
10/9/13 - $33.01
Market Cap
8.2B
Average Volume 10 Days
888.4K
EPS TTM
$-0.76
Shares Outstanding
168.4M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for INCYTE CORP (INCY)

incyte corp (INCY) Related Businessweek News

No Related Businessweek News Found

incyte corp (INCY) Details

Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of proprietary small molecule drugs primarily for oncology and inflammation. The company markets JAKAFI, an oral janus associated kinase (JAK) inhibitor for the treatment of patients with intermediate or high-risk myelofibrosis (MF), including primary MF, post-polycythemia vera MF, and post-essential thrombocythemia MF. Its product pipe line includes ruxolitinib, a JAK inhibitor, which is in Phase III clinical trial for polycythemia vera; in Phase II trial for pancreatic cancer; and in Phase I trial for the treatment of malignancies, as well as baricitinib, a JAK inhibitor, which is in Phase III trial for rheumatoid arthritis, in Phase IIb trial for psoriasis, and in Phase II trial for diabetic nephropathy. The company’s products in pipeline also comprise INC280, which is in Phase II clinical trial for the treatment of solid tumors, hepatocellular carcinoma, and non-small cell lung cancer; and INCB24360 that is in Phase II clinical trial for the treatment of metastatic melanoma and ovarian cancer; INCB40093 and INCB39110+INCB40093, which are Phase I clinical trial products for the treatment of B-lymphoid malignancies; INCB39110 that is in Phase II for myelofibrosis treatment and in Phase I for the treatment of malignancies; and INCB47986, which is in Phase I clinical trial products for the treatment of rheumatoid arthritis. It has a collaborative research and license agreements with Novartis International Pharmaceutical Ltd.; Eli Lilly and Company; and Pfizer Inc., as well as strategic collaboration arrangement with Merck. The company was founded in 1991 and is headquartered in Wilmington, Delaware.

481 Employees
Last Reported Date: 02/21/14
Founded in 1991

incyte corp (INCY) Top Compensated Officers

Chief Financial Officer and Executive Vice Pr...
Total Annual Compensation: $357.6K
Chief Commercial Officer and Executive Vice P...
Total Annual Compensation: $506.6K
Chief Drug Development & Medical Officer and ...
Total Annual Compensation: $373.4K
Executive Vice President of Human Resources
Total Annual Compensation: $354.0K
Compensation as of Fiscal Year 2013.

incyte corp (INCY) Key Developments

FDA Accepts Incyte's Supplemental New Drug Application for Jakafi(R) (ruxolitinib) and Priority Review Granted

Incyte Corporation announced that the U.S. Food and Drug Administration (FDA) has accepted for filing the supplemental New Drug Application (sNDA) for ruxolitinib as a potential treatment of patients with polycythemia vera (PV) who have had an inadequate response to or are intolerant of hydroxyurea. The sNDA includes results from the RESPONSE Phase III trial, which were recently presented at the 2014 American Society of Clinical Oncology (ASCO) annual meeting. RESPONSE was conducted under a Special Protocol Assessment (SPA) from the FDA. The Prescription Drug User Fee Act (PDUFA) date for the sNDA for ruxolitinib is set for December 5, 2014. PV is a form of blood cancer leading to the overproduction of normal red blood cells, white blood cells and platelets. Patients with uncontrolled PV have an increased risk of cardiovascular complications such as stroke, pulmonary embolism, deep vein thrombosis and heart attack. Jakafi is the first and only FDA-approved treatment for patients with intermediate or high-risk myelofibrosis (MF), including primary MF, post--polycythemia vera MF and post--essential thrombocythemia MF. Ruxolitinib is also the first JAK1/JAK2 inhibitor to demonstrate efficacy in a Phase III trial in patients with polycythemia vera and, if approved, would be the first JAK1/JAK2 inhibitor made available to patients with polycythemia vera in the U.S.

Incyte Corporation Reports Unaudited Consolidated Financial Results for the Second Quarter and Six Months Ended June 30, 2014; Provides Earnings Guidance for Fiscal 2014

Incyte Corporation reported unaudited consolidated financial results for the second quarter and six months ended June 30, 2014. For the quarter, total revenues were $99,582,000 against $101,675,000 for the same period of last year. Loss from operations was $26,187,000 against income of $17,319,000 for the same period of last year. Loss before income taxes was $36,803,000 against $2,500,000 for the same period of last year. Net loss was $36,873,000 against $2,571,000 for the same period of last year. Net loss per basic and diluted share was $0.22 against $0.02 for the same period of last year. For the six months, total revenues were $189,374,000 against $172,752,000 for the same period of last year. Loss from operations was $49,123,000 against income of $13,222,000 for the same period of last year. Loss before income taxes was $70,711,000 against $18,127,000 for the same period of last year. Net loss was $70,830,000 against $18,240,000 for the same period of last year. Net loss per basic and diluted share was $0.43against $0.13 for the same period of last year. The company now expects that 2014 net product revenues from Jakafi will be in the range of $330 million to $340 million, an increase from the previous range of $315 million to $335 million. This range excludes any product royalty revenues received from the Company's collaboration partner Novartis on sales of Jakavi(R) (ruxolitinib) outside the United States.

Incyte Corporation Announces Clinical Trial Agreement with Genentech to Evaluate Combination of Two Novel Cancer Immunotherapies

Incyte Corporation announced that it has entered into a clinical trial agreement with Genentech to evaluate the safety, tolerability and preliminary efficacy of Incyte's oral indoleamine dioxygenase-1 (IDO1) inhibitor, INCB24360, in combination with Genentech's PD-L1 immune checkpoint inhibitor, MPDL3280A, in patients with non-small cell lung cancer (NSCLC). Both INCB24360 and MPDL3280A are part of a new class of cancer treatments known as immunotherapies that are designed to enhance the body's own defenses in fighting cancer; both agents target distinct regulatory components of the immune system. Under the terms of the collaboration, Incyte and Genentech will collaborate on a non-exclusive basis to evaluate the combination. Incyte will be responsible for conducting the study and the results will be used to determine whether further clinical development of this combination is warranted.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
INCY:US $48.88 USD +0.62

INCY Competitors

Market data is delayed at least 15 minutes.

Company Last Change
ARIAD Pharmaceuticals Inc $5.76 USD -0.15
Array BioPharma Inc $3.79 USD +0.01
CTI BioPharma Corp $2.66 USD -0.13
Evotec AG €3.10 EUR +0.15
GlaxoSmithKline SAE £13.99 EGP 0.00
View Industry Companies
 

Industry Analysis

INCY

Industry Average

Valuation INCY Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 21.8x
Price/Book NM Not Meaningful
Price/Cash Flow NM Not Meaningful
TEV/Sales 18.6x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact INCYTE CORP, please visit www.incyte.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.